Related Experiment Videos
Interferon-alpha in tumor immunity and immunotherapy
Filippo Belardelli1, Maria Ferrantini, Enrico Proietti
1Laboratory of Virology, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy. belard@iss.it
Cytokine & Growth Factor Reviews
|March 20, 2002
Summary
Interferon-alpha (IFN-alpha) enhances antitumor immunity by modulating T and dendritic cells. This cytokine shows promise as an immune adjuvant for developing effective cancer vaccines.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Interferon-alpha (IFN-alpha), a type I IFN cytokine, is utilized in cancer therapy.
- Host immune mechanisms are crucial for sustained anti-tumor responses to type I IFN.
- Emerging research highlights IFN-alpha's immunomodulatory roles.
Purpose of the Study:
- To explore the immunomodulatory effects of IFN-alpha on immune cells relevant to tumor immunity.
- To investigate the role of IFN-alpha in generating durable anti-tumor responses in cancer patients.
- To identify novel strategies for cancer immunotherapy utilizing IFN-alpha.
Main Methods:
- Review of early mouse tumor models demonstrating the importance of host immunity.
- Analysis of recent studies on IFN-alpha's effects on T cells and dendritic cells.
- Examination of immune correlates in cancer patients responding to IFN-alpha therapy.
Main Results:
- IFN-alpha exhibits significant immunomodulatory activities on T cells and dendritic cells.
- These activities contribute to IFN-alpha-induced tumor immunity.
- Observed immune correlates in patients further support IFN-alpha's interaction with the immune system.
Conclusions:
- IFN-alpha plays a critical role in generating durable anti-tumor responses.
- Understanding IFN-alpha's immune interactions suggests new immunotherapy approaches.
- IFN-alpha can potentially serve as an immune adjuvant in cancer vaccine development.